Opinion

Video

MCL Therapy Selection and Sequencing

Panelists discuss the treatment- and patient-specific factors considered when determining induction therapy for treatment-naive patients with mantle cell lymphoma (MCL), including the decision between aggressive and less aggressive approaches, and how prior therapy exposure influences subsequent treatment sequencing for MCL.

  1. What treatment- and patient-specific factors do you consider when determining induction therapy for a treatment-naive patient with MCL (eg, aggressive vs less aggressive)?
  2. How do you sequence therapies for patients with MCL and how does prior therapy exposure influence your subsequent choice of treatments?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
4 experts in this video
4 experts in this video
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo